Edwin Rock - 20 Jun 2024 Form 4 Insider Report for GLYCOMIMETICS INC (GLYC)

Role
Chief Medical Officer
Signature
/s/ Brian F. Leaf, Attorney-in-Fact
Issuer symbol
GLYC
Transactions as of
20 Jun 2024
Net transactions value
+$78,824
Form type
4
Filing time
24 Jun 2024, 16:29:48 UTC
Previous filing
17 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GLYC Common Stock Purchase $48,108 +190,000 +51% $0.2532 565,403 20 Jun 2024 Direct F1
transaction GLYC Common Stock Purchase $30,716 +115,000 +20% $0.2671 680,403 21 Jun 2024 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.24 to $0.2594 per share, with a weighted average purchase price of $0.2532 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F2 The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.2579 to $0.27 per share, with a weighted average purchase price of $0.2671 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.